Suppr超能文献

同步放化疗后下咽/食管上段狭窄形成的危险因素。

Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation.

作者信息

Lee Walter T, Akst Lee M, Adelstein David J, Saxton Jerrod P, Wood Benjamin G, Strome Marshall, Butler Robert S, Esclamado Ramon M

机构信息

Head and Neck Institute, Cleveland Clinic Foundation, Ohio Desk A71, 9500 Euclid Ave., Cleveland, Ohio 44195, USA.

出版信息

Head Neck. 2006 Sep;28(9):808-12. doi: 10.1002/hed.20427.

Abstract

BACKGROUND

Concurrent chemoradiation therapy has been demonstrated to be effective as an organ-sparing treatment for select advanced head and neck squamous cell carcinoma (HNSCC). However, this treatment modality is not without side effects. One side effect is the formation of upper esophageal strictures. As concurrent chemoradiation treatment is used more frequently, it is important to identify risk factors associated with stricture formation.

METHODS

A retrospective chart review of all patients who had undergone definitive concurrent chemoradiation treatment between 1989 and 2002 was performed. Exclusion criteria included death within 1 year or persistent/recurrent disease that required surgical salvage at the primary site. The outcome measure was stricture formation as determined by both objective findings (barium swallow or endoscopy) and the need for dilation after treatment.

RESULTS

Of the 222 patients in this cohort, there were enough data for 199 patients to assess for stricture formation. Strictures developed in a total of 41 patients (21%). Significant predictive factors were a twice-daily (BID) radiation fractionation (p = .007), female sex (p = .015), and a hypopharyngeal primary site (p = .01). Age and tumor extent were not significant factors in stricture formation (p = .15 and p = .23, respectively).

CONCLUSIONS

Symptomatic strictures occur in 21% of patients undergoing concurrent chemoradiation for HNSCC. Female sex, BID radiation fractionation, and a hypopharyngeal primary site are significant predictive factors for stricture formation.

摘要

背景

同步放化疗已被证明是一种有效的保留器官的治疗方法,用于特定的晚期头颈部鳞状细胞癌(HNSCC)。然而,这种治疗方式并非没有副作用。其中一个副作用是上食管狭窄的形成。随着同步放化疗的使用越来越频繁,识别与狭窄形成相关的危险因素很重要。

方法

对1989年至2002年间接受确定性同步放化疗的所有患者进行回顾性病历审查。排除标准包括1年内死亡或原发性部位需要手术挽救的持续性/复发性疾病。结局指标是根据客观检查结果(吞咽钡剂或内镜检查)以及治疗后是否需要扩张来确定狭窄形成情况。

结果

该队列中的222例患者中,有199例患者有足够的数据来评估狭窄形成情况。共有41例患者(21%)出现狭窄。显著的预测因素是每日两次(BID)的放疗分割(p = 0.007)、女性(p = 0.015)以及下咽原发性部位(p = 0.01)。年龄和肿瘤范围不是狭窄形成的显著因素(分别为p = 0.15和p = 0.23)。

结论

接受同步放化疗的HNSCC患者中有21%出现有症状的狭窄。女性、每日两次的放疗分割以及下咽原发性部位是狭窄形成的显著预测因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验